Prevalence

From Instagram to Insta-Fired: 86% of Canadian Companies Would Fire Employees for Inappropriate Social Media Posts

Retrieved on: 
Wednesday, January 11, 2023

A large majority of Canadian companies (86%) say they would fire an employee based on inappropriate social media posts.

Key Points: 
  • A large majority of Canadian companies (86%) say they would fire an employee based on inappropriate social media posts.
  • Two-thirds of Canadian companies (65%) say they use social media to screen job applicants and say it’s an effective screening method (64%).
  • Despite the prevalence of social media, less than one-fifth of Canadian companies (18%) have a formal social media policy for employees.
  • In terms of how companies do handle social media use by employees, 37% discourage use of social media during work hours, 21% provide resources and information on professional social media etiquette, 14% block social media sites on company property (e.g., laptops and cellphones), 13% view or monitor employees’ social media accounts and 12% have access to employees’ social media accounts.

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

Retrieved on: 
Monday, January 9, 2023

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from the ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at a virtual Investor and Analyst Event on Thursday, Feb. 16, 2023.

Key Points: 
  • We also saw promising PPi elevation in our ABCC6 Deficiency trial, with a rapid initial increase at the lowest dose of INZ-701.
  • The Company will share topline pharmacokinetic, pharmacodynamic (PK/PD) and safety data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency.
  • The event will also feature presentations from members of the Inozyme management team, as well as from key opinion leaders in ENPP1 Deficiency and ABCC6 Deficiency.
  • The webcast will be accessible through the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the event.

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

Retrieved on: 
Monday, January 9, 2023

This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.

Key Points: 
  • This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.
  • ITM diagnosis is specifically associated with an overall poor prognosis and has the potential to be seriously debilitating and life threatening.
  • Furthermore, we encourage collaboration between our various researchers to assist Provectus in building the Company’s medical science platform and associated drug pipeline.
  • Provectus’ capital raising efforts will continue in 2023.

Seasoned Healthcare Executives Launch Oasis Health Partners

Retrieved on: 
Monday, January 9, 2023

MYRTLE BEACH, S.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, co-founders Brian Mathis and Kari Severson Snaza announced the launch of Oasis Health Partners, a new company focused on value-based care in rural America.

Key Points: 
  • MYRTLE BEACH, S.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, co-founders Brian Mathis and Kari Severson Snaza announced the launch of Oasis Health Partners, a new company focused on value-based care in rural America.
  • Patients enjoy dedicated health advocates and nurse practitioners, prevention and care management resources and better access to in-clinic, in-home and virtual care.
  • When we empower primary care providers, we elevate the health of local communities across America," says Kari Severson Snaza, co-founder and president of Oasis Health Partners.
  • Oasis is backed by well-known healthcare venture funds, including Triple Aim Partners and GV (formerly Google Ventures).

Derm-Biome Pharmaceuticals’ Multi-Target Topical Drug Produces Positive Results in Preclinical Study in Acne

Retrieved on: 
Monday, January 9, 2023

The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.

Key Points: 
  • The psychological impact of acne is substantial, causing profound negative social effects on the quality of life.
  • There are currently no satisfactory treatments for acne that combine high efficacy and acceptable safety.
  • The global acne treatment market size is forecast to reach as high as $16.9B USD by 2030 (Precedence Research).
  • We feel that it has significant potential to be a first-line treatment for acne and atopic dermatitis, two inflammatory skin diseases with substantial unmet need.”

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders

Retrieved on: 
Monday, January 9, 2023

NaMuscla® is the first and only licensed product for this indication in Europe and will be commercialized by Lupin’s partner Exeltis in Spain.

Key Points: 
  • NaMuscla® is the first and only licensed product for this indication in Europe and will be commercialized by Lupin’s partner Exeltis in Spain.
  • NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain1, and is characterized by the inability to relax muscles following voluntary contraction (myotonia).
  • NaMuscla® reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients2.
  • We are grateful to all stakeholders involved in the approval process, especially our partner Exeltis,” said Thierry Volle, President EMEA, Lupin.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Europe Compounding Pharmacies Market Report 2023: Sector to Grow by 8.25% Annually Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The European Compounding Pharmacies Market is projected to display significant growth represented by a CAGR of 8.25% during 2023-2028.

Key Points: 
  • The European Compounding Pharmacies Market is projected to display significant growth represented by a CAGR of 8.25% during 2023-2028.
  • The European Compounding Pharmacies Market was valued at USD 3314.80 Million in the year 2021 with Italy holding the largest market share.
  • The report analyses the Europe Compounding Pharmacies Market by Type (Oral, Topical, Ophthalmic, Injecs, and Others Types).
  • The Europe Compounding Pharmacies Market has been analysed by Country (United Kingdom, Germany, France, Italy, Spain, Russia, Turkey, Benelux, Nordic, and Rest of Europe).

Worldwide Hydroponic Vegetables Industry to 2030 - Featuring AMCO Produce, Eden Farms, Hollandia Produce and Bright Farms Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

This approach allows roots to absorb nutrients from the water and meet their growth needs.

Key Points: 
  • This approach allows roots to absorb nutrients from the water and meet their growth needs.
  • Rising prevalence of soil-borne disease caused due to microorganisms present in the soil is expected to foster the market growth of hydroponic vegetable.
  • Increasing spending on the cultivation of hydroponic vegetables by the government to meet the rising demand around the globe is projected to augment market growth.
  • All these factors are projected to augment the market growth of the hydroponic vegetables over the forecast timeframe.

Collagen Supplement Global Market Report 2022: Rising Awareness of Health Benefits Drives Adoption - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023

The global collagen supplement market size reached US$ 2.06 Billion in 2021.

Key Points: 
  • The global collagen supplement market size reached US$ 2.06 Billion in 2021.
  • Besides this, the rising awareness among the masses about the benefits of collagen supplements to prevent collagen deficiency in the body is contributing to the growth of the market.
  • This, along with the growing utilization of collagen supplements in the food and beverage (F&B) industry, is offering a positive market outlook.
  • The publisher provides an analysis of the key trends in each sub-segment of the global collagen supplement market report, along with forecasts at the global, regional and country level from 2022-2027.